Overseas Firms Struggle With Software Protocols During U.S. FDA Inspections – Bio Korea
This article was originally published in PharmAsia News
Executive Summary
OSONG, South Korea - Many firms outside the U.S. fail to designate a key person to handle the software side of clinical trials and are subsequently hauled up for the lapses via U.S. FDA warning letters over computerized validation systems, an expert on drug company information systems said during the annual Bio Korea conference in Osong, South Korea Oct. 10
You may also be interested in...
FDA Says Lack of Resources and Staff Hinder Its Foreign Inspections
Other News from Asia
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).